TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1917073

Group type: EXPERIMENTAL
Intervention: Vibration frequencies of 31.5‐63 Hz at 10 m/s2 (rms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vibration frequencies of 250‐500 Hz at 10 m/s2 (rms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vibration frequencies of 31.5‐63 Hz at 50 m/s2 (rms)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vibration frequency of 500 Hz at 50 m/s2 (rms)
Number of subjects: 18
Study: 7050710

Group type: EXPERIMENTAL
Intervention: Aspirin (0.5 g given three times a day)
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1303
Study: 3158636

Group type: EXPERIMENTAL
Intervention: Maneuver E (feedback with visual feedback of pleural and abdominal pressure)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maneuvers A, B, and D
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maneuver C
Number of subjects: 35

Group type: COMPARATOR
Intervention: All maneuvers
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maneuvers A and B
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maneuver D and E
Number of subjects: 35
Study: 31601539

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 30390203

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/Valsartan 160 mg (A/V)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/Valsartan 160 mg (N/V)
Number of subjects: 137
Study: 26930583

Group type: EXPERIMENTAL
Intervention: 50 mg artesunate and 135 mg amodiaquine fixed dose formulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study: 23903900

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2 % ropivacaine at 4 ml/h with a bolus of 0 ml
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2 % ropivacaine at 0 ml/h with a bolus of 4 ml
Number of subjects: 99

Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 99
Study: 22343599

Group type: EXPERIMENTAL
Intervention: VAS(MD1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(MD2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: WES(MD1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: WES(MD2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Pt)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Plast1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Plast2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(MD) and VAS(Plast)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Pt) and WES(MD)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(MD) and WES(MD)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(MD1) and VAS(MD2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: WES(MD1) and WES(MD2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Plast1) and VAS(Plast2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Pt) and VAS(Plast)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: VAS(Pt) and VAS(MD)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: WES(MD) and VAS(Plast)
Number of subjects: 175
Study: 20336047

Group type: EXPERIMENTAL
Intervention: Reamberin in combined treatment
Number of subjects: 138
Study: 18771056

Group type: EXPERIMENTAL
Intervention: Needle-free injection device (NFID)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard 27-gauge half-inch needle/syringe (NS)
Number of subjects: 58
Study: 16340384

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at 500 mg twice daily for 2 months, then increased to 1000 mg twice daily for 4 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study: 12679951

Group type: EXPERIMENTAL
Intervention: Endoscopic nasopancreatic drainage (ENPD)
Number of subjects: 14
Study: 10479911

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Chemotherapy (ChT)
Number of subjects: 121
Study: 8792955

Group type: EXPERIMENTAL
Intervention: Dornase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1960363

Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry consultation and follow-up at least once per week for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 80
Study: 6754510

Group type: EXPERIMENTAL
Intervention: Tolciclate 1% cream and lotion applied twice a day for about 3 weeks
Number of subjects: 278

Group type: COMPARATOR
Intervention: Clotrimazole 1% cream and lotion applied twice a day for about 3 weeks
Number of subjects: 278
Study: 30803305

Group type: COMPARATOR
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 10

Group type: COMPARATOR
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 10

Group type: COMPARATOR
Intervention: AbobotulinumtoxinA
Number of subjects: 10

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 4 U/kg/leg
Number of subjects: 10

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 4 U/kg/leg + casting
Number of subjects: 10

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 8 U/kg
Number of subjects: 10
Study: 28672098

Group type: EXPERIMENTAL
Intervention: Inhaled Budesonide 1000 μg/dose
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27269956

Group type: EXPERIMENTAL
Intervention: Ibudilast (20 mg twice daily followed by 50 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25462610

Group type: EXPERIMENTAL
Intervention: Performance Based Financing (PBF)
Number of subjects: 4916
Study: 22749817

Group type: EXPERIMENTAL
Intervention: HIFU ablation with 1 mL of iodized oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: HIFU ablation with physiologic saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HIFU ablation with iodized oil
Number of subjects: 40
Study: 19648462

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 0
Study: 16798012

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15176682

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 14597886

Group type: EXPERIMENTAL
Intervention: Revascularization and ventricular restoration procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuclear medicine studies and stress echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combining ventricular restoration with bypass surgery
Number of subjects: 0
Study: 10360854

Group type: EXPERIMENTAL
Intervention: Propofol (0.75 mg/kg for verbal command response)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Propofol (1.28 mg/kg for tetanic stimulus response)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Propofol (1.01 mg/kg for verbal command response)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Propofol (1.76 mg/kg for tetanic stimulus response)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Propofol (0.98 mg/kg for verbal command response)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Propofol (1.89 mg/kg for tetanic stimulus response)
Number of subjects: 180
Study: 7531845

Group type: EXPERIMENTAL
Intervention: AgNOR counting method 1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AgNOR counting method 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AgNOR counting method 3
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Replicate counts
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall AgNOR counts
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Technical standardization
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reproducibility
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation with prognosis
Number of subjects: 50
Study: 1826213

Group type: EXPERIMENTAL
Intervention: celiprolol 400 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: atenolol 100 mg/day
Number of subjects: 46
Study: 6411939

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional followup (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 90
Study: 31614244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5μg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0μg/kg
Number of subjects: 80
Study: 29908371

Group type: EXPERIMENTAL
Intervention: Blended-sensor (MV + XL) programming
Number of subjects: 501

Group type: COMPARATOR
Intervention: Accelerometer (XL) alone
Number of subjects: 501
Study: 27163699

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (2.0 g, 3 times per day for 14 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (2.0 g, 3 times per day for 14 days)
Number of subjects: 29
Study: 25073446

Group type: EXPERIMENTAL
Intervention: Bio-Oss
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: NanoBone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: easy-graft CLASSIC
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: easy-graft CRYSTAL
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 155
Study: 23032585

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution) injection
Number of subjects: 10
Study: 20232131

Group type: EXPERIMENTAL
Intervention: Personal digital assistant-based dietary self-monitoring
Number of subjects: 123
Study: 17416765

Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Natural menopause
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Age at menopause
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Age at menarche
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Total duration of breast mitotic activity
Number of subjects: 1601
Study: 16091268

Group type: EXPERIMENTAL
Intervention: Voluntary processing in strategy change
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Voluntary decision-making against adopting a new strategy
Number of subjects: 2
Study: 12190218

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Uninfected diabetic children (control group)
Number of subjects: 8
Study: 9584539

Group type: EXPERIMENTAL
Intervention: Special intervention (psychiatric evaluation plus 1 to 7 sessions of behavioral therapy)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Psychologically treated patients (special intervention)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Untreated patients (usual care)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Special intervention
Number of subjects: 380
Study: 8597462

Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 0
Study: 2759361

Group type: EXPERIMENTAL
Intervention: Addition of 300 ml of water to a meal
Number of subjects: 27
Study: 1165338

Group type: EXPERIMENTAL
Intervention: Delayed Feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Delayed Feedback with LOA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Immediate Feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Immediate Feedback with LOA
Number of subjects: 48

Group type: COMPARATOR
Intervention: No Feedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: No Feedback with LOA
Number of subjects: 48
Study: 29908359

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily (n = 72)
Number of subjects: 147

Group type: COMPARATOR
Intervention: placebo (n = 75)
Number of subjects: 147
Study: 28586279

Group type: EXPERIMENTAL
Intervention: Alectinib (600 mg twice daily)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 303

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 303
Study: 25565482

Group type: EXPERIMENTAL
Intervention: health‐promotion intervention
Number of subjects: 1181

Group type: COMPARATOR
Intervention: attention‐matched control intervention
Number of subjects: 1181
Study: 24171979

Group type: EXPERIMENTAL
Intervention: Hemocoagulase solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21062083

Group type: EXPERIMENTAL
Intervention: Mitosomal daunorubicin plus amlodipine
Number of subjects: 0
Study: 19484759

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP/TAZO) 80 mg/kg piperacillin/10 mg/kg tazobactam every 6 hr
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cefepime (CEF) 50 mg/kg every 8 hr
Number of subjects: 70
Study: 17121552

Group type: EXPERIMENTAL
Intervention: 2% lidocaine (2.0 mg.kg(‐1))
Number of subjects: 358
Study: 14631221

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (10 minutes of ischemia followed by 10 minutes of reperfusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 100
Study: 10989266

Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg p.o.) with ketanserin (50 mg p.o.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: MDMA (1.5 mg/kg p.o.) alone
Number of subjects: 14
Study: 9077073

Group type: EXPERIMENTAL
Intervention: LTB*-combined vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7524759

Group type: COMPARATOR
Intervention: 30 micrograms of recombinant G-CSF per day
Number of subjects: 38

Group type: COMPARATOR
Intervention: 300 micrograms of recombinant G-CSF per day
Number of subjects: 38
Study: 2884855

Group type: EXPERIMENTAL
Intervention: Doxazosin, administered once daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: Prazosin, administered twice daily
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Doxazosin and Prazosin
Number of subjects: 104
Study: 31782167

Group type: EXPERIMENTAL
Intervention: Modified four-session Comprehensive Behavioral Intervention for Tics
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine care (daily pyridoxine [50 mg] and psychoeducation)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Modified four-session Comprehensive Behavioral Intervention for Tics (3-month follow-up)
Number of subjects: 46
Study: 30307986

Group type: EXPERIMENTAL
Intervention: Patient controlled remifentanil
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 1358
Study: 28608739

Group type: EXPERIMENTAL
Intervention: AM-101 0.87 mg/mL
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 27807526

Group type: EXPERIMENTAL
Intervention: Strength Exercise Group (SEG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined Exercise Group (CEG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 36
Study: 23519139

Group type: EXPERIMENTAL
Intervention: Factor IX Complex (mean dose 35 units/kg)
Number of subjects: 11
Study: 21084137

Group type: EXPERIMENTAL
Intervention: Bilateral osteoarthrectomy and condylar reconstruction by free grafting of autogenous coronoid process with three‐dimensional simulation using Surgicase CMF™ software
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bilateral osteoarthrectomy and condylar reconstruction by free grafting of autogenous coronoid process without three‐dimensional simulation
Number of subjects: 16
Study: 19544758

Group type: EXPERIMENTAL
Intervention: Online treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 118
Study: 17144489

Group type: EXPERIMENTAL
Intervention: Improved UPPP
Number of subjects: 85

Group type: COMPARATOR
Intervention: Traditional UPPP
Number of subjects: 85
Study: 15265377

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily for 12 months)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 11475793

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9254982

Group type: EXPERIMENTAL
Intervention: High-resolution electrocardiogram (HRECG) measuring abnormal intra-QRS potentials (AIQP)
Number of subjects: 0
Study: 8217239

Group type: COMPARATOR
Intervention: Radiotherapy alone (50 Gy/5 weeks + 10-20 Gy boost)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Radiotherapy with weekly 5-FU (600 mg/m2)
Number of subjects: 59
Study: 3304622

Group type: EXPERIMENTAL
Intervention: Dexamethasone (group 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 24
Study: 30486573

Group type: EXPERIMENTAL
Intervention: GERD patients with extra-esophageal symptoms
Number of subjects: 60
Study: 26933811

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (0.04-0.05 mg/kg/day) + donor-derived mesenchymal stem cells (MSCs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard dose tacrolimus (0.07-0.08 mg/kg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus + MSCs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard dose tacrolimus
Number of subjects: 16
Study: 24935932

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor sitagliptin
Number of subjects: 10
Study: 21825083

Group type: EXPERIMENTAL
Intervention: VX-809 100 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: VX-809 200 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 20652790

Group type: EXPERIMENTAL
Intervention: One-visit root canal therapy (ORCT)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Pulpotomy with calcium-enriched mixture cement (PCEM)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Comparison of mean PI sum over 7 days
Number of subjects: 407

Group type: COMPARATOR
Intervention: Pain in response to percussion tests
Number of subjects: 407
Study: 18523884

Group type: EXPERIMENTAL
Intervention: Heat treatment at 40 degrees C for 2 hours
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group incubated at 37 degrees C
Number of subjects: 197
Study: 15853214

Group type: EXPERIMENTAL
Intervention: YM 294 (rhlL-11) at a dose of 50 microg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treatment observation group
Number of subjects: 0
Study: 12544528

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 11083035

Group type: EXPERIMENTAL
Intervention: Training programme for physicians
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study: 8864421

Group type: EXPERIMENTAL
Intervention: ANP (10 ng kg‐1 min‐1) during ANG II infusion
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ANP (10 ng kg‐1 min‐1) during NA infusion
Number of subjects: 69

Group type: COMPARATOR
Intervention: ANG II alone
Number of subjects: 69

Group type: COMPARATOR
Intervention: NA alone
Number of subjects: 69

Group type: COMPARATOR
Intervention: ANP alone
Number of subjects: 69
Study: 7689971

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Finasteride 10 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day (3 years therapy)
Number of subjects: 69
Study: 3780288

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam in conventional tablet form on the morning of operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sustained-release diazepam the night before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30988972

Group type: EXPERIMENTAL
Intervention: Self-efficacy-enhancing intervention (SEEI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (standard prenatal care)
Number of subjects: 90
Study: 27287784

Group type: EXPERIMENTAL
Intervention: Psychosocial day care programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard pharmacotherapy)
Number of subjects: 100
Study: 23984947

Group type: EXPERIMENTAL
Intervention: Oscillatory synchronization in distinct frequency-coupled networks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local oscillations or ERPs
Number of subjects: 0
Study: 22699824

Group type: EXPERIMENTAL
Intervention: BI 2536 200 mg on day 1
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BI 2536 60 mg on days 1-3
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BI 2536 (both dosages)
Number of subjects: 86
Study: 20675950

Group type: EXPERIMENTAL
Intervention: Familias Sanas (Healthy Families) educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18584516

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication (CNF)
Number of subjects: 177
Study: 15686241

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail (n = 42)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dynamic hip screw (n = 41)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dynamic hip screw
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 12883194

Group type: COMPARATOR
Intervention: SRL‐CsA‐ST group
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: SRL‐ST group
Number of subjects: 525
Study: 9888075

Group type: EXPERIMENTAL
Intervention: Nonpreserved ketorolac tromethamine 0.5% ophthalmic solution, 4 times daily for 3 days or until no ocular pain
Number of subjects: 170

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 170